Helping Alzheimer’s Patients Bring Back Memories

Alzheimer; News from the web:

The writer of the post in our link for today  developed an approach that allowed us to activate the neurons that store memory information, referred to as memory engrams, through optogenetics—that is, introducing a gene that is light sensitive into the memory engram cells of “Alzheimer’s” mice, then delivering blue light pulses to activate them—and measuring memory recall strength directly. To our surprise, we found comparable numbers of engram cells in normal healthy animals and Alzheimer’s animals, suggesting that the initial memory storage process is intact. Targeting the recall process in Alzheimer’s animals led to an improvement in their memory, which reached the performance level of normal animals.

Read all about it HERE

11 ways to prevent Alzheimer’s

Alzheimer; News from the web:

Great Article by Yahoo style where they not only give 11 ways to prevent Alzheimer’s but also refer to the appropriate research that has come up with this way to avoid Alzheimer’s.

In short: Get sleep, get moving, eat mediterranean, be social, don’t (almost) drink, loose weight, learn new things, wear helmet and belts, get balanced, manage blood pressure, quit smoking.

Don’t just read this summery, go for the full article and take some great actions today!

Read all about it HERE

A Vaccine for Alzheimer’s Disease?

Alzheimer; News from the web:

Swiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. The company’s numerous candidates and platforms target several different proteins and pathways thought to have a central role in Alzheimer’s pathology. 2020 has brought mixed news for AC Immune. In July, the company announced that their candidate tau vaccine, ACI-35.030, had shown “encouraging” safety data at a lower dose and was to be progressed to a higher-dose group. However, September brought the disappointing news that their anti-tau antibody, semorinemab, did not meet its primary efficacy endpoints in a Phase 2 trial. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.

https://www.technologynetworks.com/

Read all about it HERE